{
    "clinical_study": {
        "@rank": "142932", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Genuair\u00ae (Pressair\u2122) first; Breezhaler\u00ae (Neohaler\u2122) second"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Breezhaler\u00ae (Neohaler\u2122) first; Genuair\u00ae (Pressair\u2122) second"
            }
        ], 
        "brief_summary": {
            "textblock": "Preference study: Genuair\u00ae (Pressair\u2122) vs Breezhaler\u00ae (Neohaler\u2122) inhalers in patients with\n      COPD"
        }, 
        "brief_title": "Preference, Satisfaction and Ease of Use of Genuair\u00ae (Pressair\u2122) and Breezhaler\u00ae (Neohaler\u2122) Inhalers in Patients With COPD", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult male or female patients aged \u226540 years with stable moderate-to-severe COPD\n             according to the GOLD Guidelines classification (grades II and III): forced\n             expiratory volume in 1 second (measured between 10 to 15 minutes post-inhalation of\n             400 \u03bcg of salbutamol) is 30%\u2264FEV1<80% of the predicted normal value\n\n          -  Patients na\u00efve to both study inhaler devices, Genuair\u00ae and Breezhaler\u00ae, for at least\n             2 years\n\n          -  Agreement to participate and voluntarily sign the informed consent form\n\n        Exclusion Criteria:\n\n          -  Patients with other clinically significant uncontrolled chronic diseases,\n             particularly body malformations or diseases affecting coordination and/or motor\n             system\n\n          -  Patients unable to read product package instructions and answer patient reported\n             questionnaires (PASAPQ)\n\n          -  Patients with any other serious or uncontrolled mental health problems\n\n          -  Patients currently participating in other randomised clinical studies\n\n          -  Patients with COPD exacerbation within 6 weeks before Visit 1 and patient\n             hospitalised for COPD exacerbation within 3 months prior to Visit 1\n\n          -  Patients with any other conditions that, in the investigator's opinion, might\n             indicate the patient to be inappropriate for the study\n\n          -  Patient likely to be uncooperative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915784", 
            "org_study_id": "M/34273/41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "description": "Inhaler with placebo only. Once daily, for 14 days.", 
                "intervention_name": "Genuair\u00ae", 
                "intervention_type": "Device", 
                "other_name": "Pressair\u2122"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "description": "Inhaler with placebo only. Once daily, for 14 days.", 
                "intervention_name": "Breezhaler\u00ae", 
                "intervention_type": "Device", 
                "other_name": "Neohaler\u00ae"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Almirall investigative site 2"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany"
                    }, 
                    "name": "Almirall investigative site 1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Almirall investigative site 3"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain"
                    }, 
                    "name": "Almirall investigative site 4"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Almirall investigative site 5"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle upon Tyne", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Almirall investigative site 6"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Study Evaluating Preference, Satisfaction and Ease of Use of Genuair\u00ae (Pressair\u2122) and Breezhaler\u00ae (Neohaler\u2122) Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients", 
        "overall_official": {
            "affiliation": "Almirall, S.A.", 
            "last_name": "Jordi Estruch, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients will be asked to answer which device they prefer after 2 weeks of daily practice recorded via PASAPQ (Patient Satisfaction and Preference Questionnaire) a self-administered, 15-item measure of respiratory inhalation device satisfaction and preference. The PASAPQ 15-item instrument includes 13 satisfaction items [using a Likert-type scale from 1 (very dissatisfied) to 7 (very satisfied)], a preference item, and a question on willingness to continue using the device.", 
            "measure": "Percentage of patients who prefer Genuair\u00ae (Pressair\u2122) versus Breezhaler\u00ae (Neohaler\u2122) at Visit 2", 
            "safety_issue": "No", 
            "time_frame": "14 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915784"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients will be asked to rate the overall satisfaction with each device using a Likert-type scale (from 1 [very dissatisfied] to 7 [very satisfied]) after 2 weeks of daily practice recorded via PASAPQ (Patient Satisfaction and Preference Questionnaire) a self-administered, 15-item measure of respiratory inhalation device satisfaction and preference. The PASAPQ 15-item instrument includes 13 satisfaction items [using a Likert-type scale from 1 (very dissatisfied) to 7 (very satisfied)], a preference item, and a question on willingness to continue using the device.", 
                "measure": "Mean for the overall satisfaction score with Genuair\u00ae (Pressair\u2122) and Breezhaler\u00ae (Neohaler\u2122) at Visit 2", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }, 
            {
                "description": "The correct use of each device will be assessed measuring the errors made by patients when using each device after 2 weeks of daily practice\nCritical errors for each inhaler device are defined as those that compromise the potential benefit of the treatment such as impeding drug deposition in the lungs or the delivery of a sufficient dose", 
                "measure": "Percentage of patients making at least 1 critical error with Genuair\u00ae (Pressair\u2122) and Breezhaler\u00ae (Neohaler\u2122) at Visit 2", 
                "safety_issue": "No", 
                "time_frame": "14 Days"
            }
        ], 
        "source": "Almirall, S.A.", 
        "sponsors": {
            "collaborator": {
                "agency": "Forest Laboratories", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Almirall, S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}